Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Hyperparathyroidism

• PTH Attenuation Trial in Hemodialysis-2
• PTH Attenuation Trial in Hemodialysis-1
• A Study of SHR6508 in Secondary Hyperparathyroidism
• A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation
• Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
• Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
• Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment
• Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients
• Effect of Vitamin D Supplement on Disease Activity in SLE
• A Trial of SHR6508 in Secondary Hyperparathyroidism
• A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism
• 18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
• Vitamin D Metabolism in Patients With Endocrine Disorders
• Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).
• Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment
• Osteoporosis in Primary Hyperparathyroidism
• A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
• Bilateral Superficial Cervical Plexus Block in Thyroid/Parathyroid Surgery
• A Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
• The Effect of Etelcalcetide on CKD-MBD
• Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
• Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia
• Phase 3 Study of SK-1403
• Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)
• Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism
• 18F-Fluorocholine for the Detection of Parathyroid Adenomas
• Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects
• Study of Etelcalceide in Pediatric Subjects With Secondary Hyperparathyroidism and CKD on Hemodialysis
• SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis
• Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
• Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney D
• Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
• A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416
• Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
• Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism
• Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT
• The Effect of Diuretics on Mineral and Bone Disorder in Chronic Kidney Disease Patients
• Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease
• Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
• Corticosteroid Rhythms in Hypoparathyroid Patients
• Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients.
• Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis
• A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis
• Phase 3 Study of KHK7580
• Phase 3 Study of KHK7580
• Phase 3 Study of KHK7580
• Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
• Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism
• Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis
• Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients
• The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis
• Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
• Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
• Optimal Anemia Treatment in End Stage Renal Disease (ERSD)
• Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?
• Phase 2 Study of KHK7580
• Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy
• Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis
• Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis
• A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis
• Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis
• The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid
• Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis
• EC17 for Intraoperative Imaging for Parathyroidectomy
• Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.
• Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
• Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
• A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
• Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
• OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism
• Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
• Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
• Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
• Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
• Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
• The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
• Vitamin D Supplementation in HIV-infected Youth
• A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
• Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
• Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients
• Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism
• Denosumab in Primary Hyperparathyroidism
• A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients
• Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)
• An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism
• Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)
• Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients
• Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
• Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease
• Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder
• A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
• Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
• One Week Comparison Study of PTH and PTHrP Infusions
• Vitamin D Repletion in Primary Hyperparathyroidism
• Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease
• Pediatric Chronic Kidney Disease Safety and Efficacy
• Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
• Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate
• Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism
• Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)
• Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
• Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis
• Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation
• LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients
• Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism
• Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery
• Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
• Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers
• Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
• Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism
• Evaluation of a Cincalcet Suppression Test
• Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level
• Trial to Optimize Mineral Outcomes in Dialysis Patients
• Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density
• Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease
• FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
• Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism
• Vitamin D Supplementation After Parathyroid Surgery
• Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
• Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy
• Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
• Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?
• Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients
• A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism
• A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)
• PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice
• Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose
• Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects
• Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)
• Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)
• 20070360 Incident Dialysis
• Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism
• Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)
• Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism
• Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.
• Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
• Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)
• Effect of Vitamin D Treatment in Primary Hyperparathyroidism
• Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis
• Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects
• Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients
• Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions
• Oral Paricalcitol in Kidney Transplant Recipients
• One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
• Regulation of Bone Formation in Renal Osteodystrophy
• Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)
• Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis
• How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
• Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects
• Interaction Between Anaesthetics and Methylene Blue
• Treatment of Secondary Hyperparathyroidism in the Uremic Patient
• A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection
• A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis
• Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
• A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)
• A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis
• Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets
• Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients
• Evaluation of Colecalciferol Substitution in Dialysis Patients
• Post Transplant Study
• ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
• 7 Day Continuous Parathyroid Hormone IV Infusion
• The Effects of Alendronate After Cure of Primary Hyperparathyroidism
• E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
• Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism
• Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
• Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
• Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
• A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease
• CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
• A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)
• Active Vitamin D Effect on Left Ventricular Hypertrophy
• ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism
• START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
• Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism
• SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism
• Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)
• Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
• Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium
• Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis
• A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis
• Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients
• A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
• A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer
• Studies of Elevated Parathyroid Activity